Improving diagnosis and management of Pre-Eclampsia
Posted: - 19th October 2020
Over 250 women in our region have been safely discharged from hospital thanks to the implementation of Placental Growth Factor Testing which is used to help diagnose Pre-Eclampsia.
Pre-Eclampsia is a condition that affects some pregnant women, usually during the second half of pregnancy. It causes high blood pressure and protein in the urine and, if not diagnosed and closely monitored, it can lead to potentially life-threatening complications.
Since being first implemented in Calderdale and Huddersfield NHS Foundation Trust in October 2019, the test has led to improvements in diagnosis and management of women with Pre-Eclampsia. It eliminates the risk of poor prediction of the condition and reduces the risk of unnecessary hospitalisation for women who will not go on to develop it. This creates the potential to free up hospital beds and provides both an improved patient experience and financial benefit for the NHS. The test is now live in seven sites across the region.
Find out more about our work in our Impact Report
See what patients have said about the test below and watch our video for further information about the test.
I am so glad I had the Placental Growth Factor ratio test performed – after having headaches I came to the Maternity Assessment Centre for a review. My blood pressure was normal and the blood test showed I was low risk of Pre-Eclampsia – this was such reassurance for me and eased some of the anxiety I had
I went to the Maternity Assessment Centre with headaches, blurred eyes and noticed swelling, I had the blood test – it showed I was at high risk of Pre-Eclampsia. Even though it showed I was at high risk I was very happy to have had the test as now I have the right care and plan to keep me and my baby safe
